Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | ENERGY: Phase II/III study of nipocalimab in patients with wAIHA

Irina Murakhovskaya • 12 Dec 2022
ASH 2022
Anemias Autoimmune Hemolytic Anemia Rare Diseases Antibodies Nipocalimab
ENERGY

Irina Murakhovskaya, MD, Montefiore Medical Center, Albert Einstein College of Medicine, New York City, NY, comments on the design of the ENERGY study (NCT04119050), a Phase II/III trial of nipocalimab, a neonatal Fc receptor (FcRn) blocker, in patients with warm autoimmune hemolytic anemia (wAIHA), explaining the mechanism of action of this drug. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Incyte: Research Funding; Alexion: Research Funding; Annexon: Research Funding; Kezar: Research Funding; Rigel: Consultancy, Research Funding; Sanofi: Consultancy, Research Funding; Novartis: Consultancy, Research Funding.

More from Irina Murakhovskaya

Impact of obesity on outcomes in patients with primary ITP
1:45
Impact of obesity on outcomes in patients with primary ITP
Irina Murakhovskaya • 12 Dec 2022
Treatment options for first-line & R/R wAIHA and unmet needs in this field
2:24
Treatment options for first-line & R/R wAIHA and unmet needs in this field
Irina Murakhovskaya • 12 Dec 2022

Related Videos

BPDCN: unmet needs, CD123-targeted therapies and novel targets
15:50
BPDCN: unmet needs, CD123-targeted therapies and novel targets
Naveen Pemmaraju • 19 Sep 2026
Managing ruxolitinib-associated anemia in myelofibrosis: dose reduction and add-on therapies
1:48
Managing ruxolitinib-associated anemia in myelofibrosis: dose reduction and add-on therapies
Ciro Rinaldi • 10 Sep 2026
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
2:19
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
1:39
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
Elena Zamagni • 25 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals